Enterprise Value
22.3M
Cash
44.23M
Avg Qtr Burn
-10.51M
Short % of Float
3.36%
Insider Ownership
0.31%
Institutional Own.
9.39%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CRB-701 Details Solid tumor/s, Urothelial cancer | Phase 1 Initiation | |
CRB-601 Details Solid tumor/s | IND Submission | |
Lenabasum Details Genetic disorder, Chronic inflammatory disorder, Rare genetic disease, Inflammatory disease | Failed Discontinued | |
Lenabasum Details Cystic fibrosis | Failed Discontinued | |
Lenabasum Details Systemic sclerosis | Failed Discontinued | |
Lenabasum (JBT-101) Details Autoimmune disease | Failed Discontinued |